Free Trial

Stocks Solid as Pfizer Up Efficacy

EQUITIES

The S&P 500 held just below alltime highs Wednesday, inching very slightly higher. After an uninspiring start, equities were lifted as Pfizer presented further results of their COVID-19 vaccine candidate, upping the efficacy from an initial estimate of 90% to 95% - flagging that there are no risks of side effects to older vaccine-takers either.

Financials and energy outperform, with industrials not far behind. Healthcare and tech were the laggards. Airlines traded well, with United Airlines & American Airlines adding over 4% apiece.

E-mini S&P volumes were a little lower than recent averages, with no tier 1 data releases to excite markets. Suitably, the VIX retreated to its lowest levels since August.

MNI London Bureau | +44 203-865-3809 | edward.hardy@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.